[go: up one dir, main page]

MX2017016884A - Formulacion farmaceutica estable de una proteina anti-tnfa. - Google Patents

Formulacion farmaceutica estable de una proteina anti-tnfa.

Info

Publication number
MX2017016884A
MX2017016884A MX2017016884A MX2017016884A MX2017016884A MX 2017016884 A MX2017016884 A MX 2017016884A MX 2017016884 A MX2017016884 A MX 2017016884A MX 2017016884 A MX2017016884 A MX 2017016884A MX 2017016884 A MX2017016884 A MX 2017016884A
Authority
MX
Mexico
Prior art keywords
formulation
tnf
adalimumab
protein
pharmaceutical formulation
Prior art date
Application number
MX2017016884A
Other languages
English (en)
Inventor
Raúl Campos García Víctor
PIÑA LARA Nelly
Patricia Miranda Hernández Mariana
SALAZAR CEBALLOS Rodolfo
Octavio Pérez Ramírez Néstor
Eduardo Epinosa De La Garza Carlos
De Lourdes MUCIÑO ALCÁNTARA María
GONZÁLEZ SANTOYO Germán
Bolivar Vichido Mariana
Germán Hernández García Antonio
Jardón Castillo Maribel
Pérez Medina Martínez Victor
Original Assignee
Probiomed S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiomed S A De C V filed Critical Probiomed S A De C V
Priority to MX2017016884A priority Critical patent/MX2017016884A/es
Priority to PCT/IB2018/060293 priority patent/WO2019123283A1/es
Publication of MX2017016884A publication Critical patent/MX2017016884A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención describe una nueva formulación líquida para Adalimumab, un anticuerpo monoclonal recombinante dirigido contra el TNFa en alta concentración (20 a 100 mg/mL), en presencia de una solución amortiguadora de pH de citratos, que mantiene un pH de 5.2, adicionada con polisorbato, manitol y cloruro de sodio utilizado como agente tonificante. Esta formulación hace uso de un menor número de excipientes que la formulación descrita en el estado de la técnica, mientras que mantiene las propiedades fisicoquímicas, biológicas, farmacológicas y de seguridad de Adalimumab. Por último, esta formulación es útil para contener Adalimumab en su uso comercial como agente bioterapéutico de administración parenteral para tratar enfermedades autoinmunes en las cuales se presenta una elevación patológica del TNFa.
MX2017016884A 2017-12-19 2017-12-19 Formulacion farmaceutica estable de una proteina anti-tnfa. MX2017016884A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2017016884A MX2017016884A (es) 2017-12-19 2017-12-19 Formulacion farmaceutica estable de una proteina anti-tnfa.
PCT/IB2018/060293 WO2019123283A1 (es) 2017-12-19 2018-12-19 Formulación farmacéutica estable de una proteína anti-tnfα

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2017016884A MX2017016884A (es) 2017-12-19 2017-12-19 Formulacion farmaceutica estable de una proteina anti-tnfa.

Publications (1)

Publication Number Publication Date
MX2017016884A true MX2017016884A (es) 2019-06-20

Family

ID=66993169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016884A MX2017016884A (es) 2017-12-19 2017-12-19 Formulacion farmaceutica estable de una proteina anti-tnfa.

Country Status (2)

Country Link
MX (1) MX2017016884A (es)
WO (1) WO2019123283A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
KR101653082B1 (ko) * 2012-03-07 2016-08-31 일라이 릴리 앤드 캄파니 Il-17 항체 제제
EP2946767B1 (en) * 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
WO2016120413A1 (en) * 2015-01-28 2016-08-04 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies

Also Published As

Publication number Publication date
WO2019123283A1 (es) 2019-06-27

Similar Documents

Publication Publication Date Title
Sibley et al. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease
RU2586289C1 (ru) Терапевтический или профилактический агент от дисфункции мейбомиевых желез или блокады мейбомиевых желез
US20220233632A1 (en) Modulators of complement activity
JP2015508774A5 (es)
JP2016172740A (ja) 改良型高濃度抗ｔｎｆアルファ抗体液体製剤
JP2021105051A (ja) Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
RU2017146657A (ru) Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона
EP3345613A4 (en) PHARMACEUTICAL COMPOSITION WITH FUSION PROTEIN WITH FUSIONED TUMORPENETRATING PEPTIDE AND ANTI-ANGIOGENESIS AGENT AS ACTIVE AGENT FOR THE PROPHYLAXIS AND TREATMENT OF CANCER OR ANGIOGENIC ASSOCIATED DISEASES
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
KR20180094913A (ko) 보체 활성의 조절인자
TW201938184A (zh) 補體活性之調節劑
EA201991078A1 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
Guo et al. Ethyl pyruvate ameliorates experimental colitis in mice by inhibiting the HMGB1-Th17 and Th1/Tc1 responses
Chen et al. Case report A case of refractory intestinal Behçet’s disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody
Korsten et al. Rapid healing of peripheral ulcerative keratitis in rheumatoid arthritis with prednisone, methotrexate and adalimumab combination therapy
MX2017016884A (es) Formulacion farmaceutica estable de una proteina anti-tnfa.
EA201992685A1 (ru) Раствор леводопы для инфузий
US20210024928A1 (en) C/ebp alpha sarna compositions and methods of use
CL2020001122A1 (es) Formulación farmacéutica estable de una proteína de fusión.
JP2008538098A (ja) ボンベシン／ガストリン放出ペプチドアンタゴニストの、炎症性状態、急性肺損傷及び双極性障害の治療のための使用
CN111000982A (zh) Amhr2重组蛋白或融合蛋白在制备amh信号轴异常活化相关疾病治疗药物中的用途
ES2986042T3 (es) Péptido y su uso en la preparación de medicamentos para el tratamiento de enfermedades inflamatorias y del dolor
Flipo et al. Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study
Bubna et al. Secukinumab: In psoriasis and beyond
RU2019140198A (ru) Способ применения элементарной ртути для лечения онкологических заболеваний